Introduction
============

Renal cell carcinoma (RCC) is the most common malignant tumor affecting the kidneys, accounting for about 90% of kidney carcinomas.[@b1-ott-12-119] Approximately 63,990 new RCC cases were diagnosed in the USA in 2017, and these were associated with an estimated 14,400 deaths.[@b2-ott-12-119] There are two common histological subtypes of RCC. Clear-cell RCC (ccRCC) is the most common, accounting for 70%--80% of all renal cancer cases. Papillary RCC (pRCC) represents another 10%--20% of cases.[@b3-ott-12-119],[@b4-ott-12-119] Approximately 25%--30% of patients with RCC present with advanced or metastatic disease, and the 5-year survival rate is poor.[@b5-ott-12-119]

DNA methylation within the promoter regions is an important mechanism underlying epigenetic modifications, which may cause inactivation of gene expression and play a crucial role in the carcinogenesis, progression, and prognosis of various human cancers.[@b6-ott-12-119]--[@b8-ott-12-119] Previous studies have suggested that promoter methylation of some cancer-related genes is found in RCC, such as *HOXB13*[@b9-ott-12-119] and *CDKN2A*/*2B*.[@b10-ott-12-119] *RASSF1A* is a key isoform of *RASSF1* located on the chromosomal region 3p21.3.[@b11-ott-12-119] An important tumor suppressor gene, *RASSF1A* is involved in cell cycle regulation, microtubule stabilization, cellular adhesion and motility, and cell apoptosis.[@b12-ott-12-119]--[@b14-ott-12-119]

*RASSF1A* promoter methylation has been reported in tissue, blood, and urine samples from patients with RCC.[@b15-ott-12-119]--[@b17-ott-12-119] There are, however, inconsistent results regarding the level of *RASSF1A* promoter methylation in patients with RCC and controls. For example, Ellinger et al reported that the *RASSF1A* promoter had a similar methylation rate in RCC and adjacent normal tissue samples.[@b18-ott-12-119] In contrast, *RASSF1A* promoter methylation was more frequent in RCC than in adjacent normal tissue samples in a study by Loginov et al.[@b19-ott-12-119] With this background of conflicting results, we conducted a meta-analysis to assess differences in *RASSF1A* promoter methylation between RCC and control tissue, blood, and urine samples. Moreover, we evaluated the association of *RASSF1A* promoter methylation with clinicopathologic features and prognosis in patients with RCC.

Materials and methods
=====================

Search strategy
---------------

A systematic literature search of the PubMed, EMBASE, EBSCO, Wanfang, and CNKI databases was conducted to identify eligible studies published through December 1, 2017, without any language restrictions. The following keywords and scientific search terms were used: (kidney OR renal) AND (cancer OR tumor OR neoplasm OR carcinoma) AND (methylation OR methylated OR hypermethylation OR epigene^\*^) AND (RAS association domain family protein 1A OR RASSF1A OR RASSF1 OR RAS association domain family protein 1). We manually searched the relevant references from all eligible articles to find other potential publications.

Selection criteria
------------------

Articles that met the following inclusion criteria were selected for the meta-analysis: 1) patients were confirmed with adult RCC by histopathologic examination; 2) studies reported sufficient data to evaluate differences in *RASSF1A* promoter methylation between the RCC and control groups; 3) studies had sufficient data to assess the correlation of *RASSF1A* promoter methylation with clinicopathologic features; and 4) studies provided enough survival data to evaluate the prognostic effect of *RASSF1A* promoter methylation in RCC. When multiple papers using the same patient population were published, the study with more information was included in the meta-analysis.

Data extraction
---------------

The following information was extracted from the included publications: surname of the first author, year of publication, country, ethnic population, cancer stage, mean or median age, sample type, detection method, histologic type, number of cases and controls, survival data with multivariate analysis, and clinicopathologic features such as age (≥50 vs \<50 years), gender (male vs female), tumor grade (3--4 vs 1--2), clinical stage (3--4 vs 1--2), T classification (pT2--4 vs pT1), histologic subtypes (pRCC vs ccRCC), lymph node metastasis (yes vs no), and distant metastasis (yes vs no).

The Cancer Genome Atlas (TCGA) dataset
--------------------------------------

Clinical information for RCC, which included two sets of samples (methylation 450 K dataset: 275 pRCCs and 319 ccRCCs), was downloaded from the TCGA data portal (<https://portal.gdc.cancer.gov/repository>). The cutoff value of *RASSF1A* promoter methylation was set by its median value. The association between clinicopathologic characteristics and *RASSF1A* promoter methylation was analyzed using logistic regression (R; v.3.4.3). Multivariate Cox analysis was used to analyze the impact of *RASSF1A* promoter methylation on overall survival (R; v.3.4.3).

Statistical analysis
--------------------

All data analyses were performed using Stata software 12.0 (StataCorp LP, College Station, TX, USA). Differences in *RASSF1A* promoter methylation between RCC and control samples and the correlation of *RASSF1A* promoter methylation with the clinicopathologic characteristics of patients with RCC were calculated using pooled ORs and the corresponding 95% CIs. Overall HRs with their 95% CIs were also calculated to determine the prognostic role of *RASSF1A* promoter methylation, using multivariate analysis if possible. The Cochran's Q statistic was used to estimate possible heterogeneity among studies.[@b20-ott-12-119],[@b21-ott-12-119] A random-effects model was applied in the meta-analysis. When substantial heterogeneity was measured (*P*\<0.1), a sensitivity analysis was carried out to determine the influence of an individual study on the pooled OR and heterogeneity by deleting one study at a time.[@b22-ott-12-119],[@b23-ott-12-119] For results covered by more than nine studies, possible publication bias was detected with Egger's test.[@b24-ott-12-119] We performed trial sequential meta-analyses (TSA) to reduce type I error and to calculate the estimated required sample size information.[@b25-ott-12-119],[@b26-ott-12-119] For significant results with more than one study, the type I error rate was set at 5% and the type II error rate was considered to be 20% (a statistical test power of 80%). The relative risk reduction was set at 20% in the meta-analysis. If the cumulative Z-curve crossed the trial sequential monitoring boundary or the required information size, the statistical evidence was deemed conclusive. Otherwise, additional studies would be needed for a definitive result.[@b27-ott-12-119],[@b28-ott-12-119]

Results
=======

Study characteristics
---------------------

[Figure 1](#f1-ott-12-119){ref-type="fig"} summarizes the details of the study selection procedure; 22 publications with a total of 1,421 patients with RCC and 724 controls fulfilled the inclusion criteria and were selected for the meta-analysis.[@b15-ott-12-119]--[@b19-ott-12-119],[@b29-ott-12-119]--[@b45-ott-12-119] Of the included publications, 15 assessed differences in *RASSF1A* promoter methylation between RCC and control samples using tissue samples and 6 used blood or urine samples. Sixteen studies evaluated the relationships between *RASSF1A* promoter methylation and the clinicopathologic characteristics of patients with RCC. Two studies reported information on survival in patients with RCC using multivariate analysis. The baseline characteristics of the included publications are presented in [Tables 1](#t1-ott-12-119){ref-type="table"} and [S1](#SD1-ott-12-119){ref-type="supplementary-material"}.

Correlation between *RASSF1A* promoter methylation and RCC in cancer vs control tissue samples
----------------------------------------------------------------------------------------------

In 15 studies that included the comparison of 829 patients with RCC and 467 adjacent/normal tissue samples ([Figure 2](#f2-ott-12-119){ref-type="fig"}), *RASSF1A* promoter methylation was notably higher in RCC than in adjacent/normal tissue samples (OR=5.64, 95% CI=1.82--17.51, *P*=0.003).

Subgroup and sensitivity analyses in cancer vs control tissue samples
---------------------------------------------------------------------

We conducted subgroup analyses by ethnicity (Asians and Caucasians) and testing method (methylation-specific polymerase chain reaction \[MSP\] and non-MSP) ([Table 2](#t2-ott-12-119){ref-type="table"}). In the ethnicity analysis, *RASSF1A* promoter methylation was associated with RCC in Caucasians (OR=4.90, 95% CI=1.45--16.64, *P*=0.011), but not in Asians (OR=9.27, 95% CI=0.35--243.63, *P*=0.182). In the testing method analysis, *RASSF1A* promoter methylation was associated with RCC in the MSP subgroup (OR=16.32, 95% CI=5.25--50.69, *P*\<0.001), but not in the non-MSP subgroup (OR=1.85, 95% CI=0.27--12.48, *P*=0.527).

There was evidence of significant heterogeneity in cancer vs control tissue samples, so we performed a sensitivity analysis. We successively removed four studies -- Tokinaga et al[@b38-ott-12-119] in Japan, Costa et al[@b33-ott-12-119] in Portugal, Gonzalgo et al[@b36-ott-12-119] in the USA, and Onay et al[@b32-ott-12-119] in Turkey -- and recalculated the overall OR (OR=19.78, 95% CI=11.09--35.29, *P*\<0.001), resulting in no heterogeneity (*P*=0.693).

Correlation between *RASSF1A* promoter methylation and RCC in cancer vs control blood or urine samples
------------------------------------------------------------------------------------------------------

In four studies that included the comparison of 237 patients with RCC with 142 nonmalignant blood samples, *RASSF1A* promoter methylation was significantly more likely in RCC than in nonmalignant blood samples (OR=11.70, 95% CI=4.82--28.39, *P*\<0.001; [Figure 2](#f2-ott-12-119){ref-type="fig"}). In addition, in a comparison of 76 RCCs and 115 nonmalignant urine samples, *RASSF1A* promoter methylation was significantly higher in RCC than in nonmalignant urine samples (OR=17.54, 95% CI=6.60--46.66, *P*\<0.001; [Figure 2](#f2-ott-12-119){ref-type="fig"}).

Correlation of *RASSF1A* promoter methylation with age and gender in RCC
------------------------------------------------------------------------

Seven studies that included 321 patients with RCC demonstrated that *RASSF1A* promoter methylation was not correlated with age (OR=1.00, 95% CI=0.50--2.04, *P*=0.99; [Figure 3](#f3-ott-12-119){ref-type="fig"}). Eight studies that included 537 patients with RCC showed that *RASSF1A* promoter methylation was not correlated with gender (OR=0.95, 95% CI=0.51--1.76, *P*=0.86; [Figure 3](#f3-ott-12-119){ref-type="fig"}).

Correlation of *RASSF1A* promoter methylation with lymph node status and distant metastasis in RCC
--------------------------------------------------------------------------------------------------

In seven studies that included 438 patients with RCC, *RASSF1A* promoter methylation was not associated with lymph node metastasis (OR=1.72, 95% CI=0.76--3.87, *P*=0.192; [Figure 4](#f4-ott-12-119){ref-type="fig"}). Four studies that included 257 patients with RCC showed that there was no correlation between *RASSF1A* promoter methylation and distant metastasis (OR=1.66, 95% CI=0.75--3.69, *P*=0.21; [Figure 4](#f4-ott-12-119){ref-type="fig"}).

Correlation of *RASSF1A* promoter methylation with tumor grade and clinical stage in RCC
----------------------------------------------------------------------------------------

In 13 studies that included 686 patients with RCC, a significant relationship was observed between *RASSF1A* promoter methylation and tumor grade (OR=3.59, 95% CI=1.85--6.95, *P*\<0.001; [Figure 5](#f5-ott-12-119){ref-type="fig"}). *RASSF1A* promoter methylation was also linked to clinical stage in eight studies that included 463 patients with RCC (OR=2.15, 95% CI=1.34--3.45, *P*=0.001; [Figure 5](#f5-ott-12-119){ref-type="fig"}).

Correlation of *RASSF1A* promoter methylation with T classification and histologic subtypes in RCC
--------------------------------------------------------------------------------------------------

In seven studies that included 306 patients with RCC, a significant correlation was found between *RASSF1A* promoter methylation and T classification (OR=2.66, 95% CI=1.11--6.39, *P*=0.029; [Figure 6](#f6-ott-12-119){ref-type="fig"}). *RASSF1A* promoter methylation was also significantly associated with histologic subtypes in eight studies that included 472 patients with RCC (OR=2.91, 95% CI=1.61--5.23, *P*\<0.001; [Figure 6](#f6-ott-12-119){ref-type="fig"}).

Prognostic role of *RASSF1A* promoter methylation using multivariate analysis
-----------------------------------------------------------------------------

Kawai et al reported that *RASSF1A* promoter methylation was a poor prognostic factor in terms of cancer-specific survival among 179 patients with ccRCC (HR=1.78, 95% CI=1.18--2.78).[@b31-ott-12-119] Klacz et al reported that *RASSF1A* promoter methylation was not associated with overall survival using multivariate analysis among 58 patients with ccRCC.[@b16-ott-12-119] More studies with large patient population are needed to further investigate the prognostic role of *RASSF1A* promoter methylation in RCC.

Publication bias
----------------

There was no evidence of publication bias using Egger's test for the comparison of RCC vs control tissue samples (*P*=0.782) or in relation to tumor grade (*P*=0.547; [Figure 7](#f7-ott-12-119){ref-type="fig"}).

Trial sequential meta-analysis
------------------------------

As shown in [Figures 8](#f8-ott-12-119){ref-type="fig"} and [9](#f9-ott-12-119){ref-type="fig"}, based on the a priori anticipated information size method for significant results, when cancer was compared with control tissue samples, the cumulative Z-curve crossed the trial sequential monitoring boundary and the required information size ([Figure 8](#f8-ott-12-119){ref-type="fig"}), suggesting conclusive results. When cancer was compared with control blood or urine samples, the cumulative Z-curve was more than the conventional boundary, but did not cross the trial sequential monitoring boundary ([Figure 8](#f8-ott-12-119){ref-type="fig"}), which suggests that more studies are needed to inform these two results. In relation to tumor grade, clinical stage, and histologic subtypes, the cumulative Z-curve was more than the trial sequential monitoring boundary ([Figures 8](#f8-ott-12-119){ref-type="fig"} and [9](#f9-ott-12-119){ref-type="fig"}), which suggests that additional studies are not necessary. In relation to T classification, the cumulative Z-curve crossed the conventional boundary, but did not cross the trial sequential monitoring boundary ([Figure 8](#f8-ott-12-119){ref-type="fig"}), suggesting that further studies are essential.

TCGA dataset
------------

After adjusting for tumor stage (stage 3--4 vs stage 1--2) and tumor histology (pRCC vs ccRCC), *RASSF1A* promoter methylation was not associated with overall survival using multivariate analysis (HR=0.921, *P*=0.687) in 567 RCCs.

*RASSF1A* promoter methylation was not significantly linked to gender (594 patients: OR=1.35, 95% CI=0.95--1.91, *P*=0.094), but it did correlate with clinical stage (568 patients: *P*=0.023) and tumor histology (594 patients: pRCC vs ccRCC: OR=23.19, 95% CI=15.07--35.7, *P*\<0.001; [Table 3](#t3-ott-12-119){ref-type="table"}).

Discussion
==========

Tumor suppressor genes are commonly inactivated via promoter methylation within the CpG islands, which may affect several biological processes, including cell proliferation, cell death, cell migration, and cell invasion, and contribute to the initiation and progression of human cancers.[@b46-ott-12-119],[@b47-ott-12-119] Studies have indicated that methylation of the promoter of the tumor suppressor gene *RASSF1A* reduces its expression, which may play an important role in RCC carcinogenesis.[@b40-ott-12-119],[@b43-ott-12-119] However, potential differences in methylation between RCC and control tissue samples have remained unclear owing to conflicting evidence from previous studies. Two studies showed that *RASSF1A* promoter methylation correlated negatively with RCC.[@b33-ott-12-119],[@b38-ott-12-119] Four studies reported no association between *RASSF1A* promoter methylation and RCC.[@b18-ott-12-119],[@b32-ott-12-119],[@b34-ott-12-119],[@b36-ott-12-119] Also, nine other studies showed that *RASSF1A* promoter methylation correlated positively with RCC.[@b19-ott-12-119],[@b37-ott-12-119],[@b39-ott-12-119]--[@b45-ott-12-119] The present meta-analysis including all eligible publications with large patient populations demonstrated that *RASSF1A* promoter methylation was notably higher in RCC than in adjacent or normal tissue samples; TSA revealed that the result was conclusive. This suggests that *RASSF1A* promoter methylation is significantly associated with RCC carcinogenesis.

When RCC was compared with control tissue samples, a subgroup analysis of ethnicity showed that *RASSF1A* promoter methylation was associated with RCC in Caucasians, but not in Asians, which suggests that only the Caucasian population is susceptible to *RASSF1A* promoter methylation. A subgroup analysis of detection method demonstrated that *RASSF1A* promoter methylation correlated with RCC in the MSP subgroup, but not in the non-MSP subgroup, which indicates that the MSP method may be sensitive to the detection of *RASSF1A* promoter methylation. We performed a sensitivity analysis because substantial heterogeneity was measured in the comparison of cancer and control tissue samples. When four studies[@b32-ott-12-119],[@b33-ott-12-119],[@b36-ott-12-119],[@b38-ott-12-119] were successively removed and the pooled OR was recalculated, remaining significant, there was no evidence of heterogeneity (*P*=0.693). It is possible that the main cause of heterogeneity in this meta-analysis was contamination of adjacent normal tissue samples by cancer cells in these four studies. In addition, Egger's test showed no publication bias. The relevant analyses supported the stability and credibility of our results.

*RASSF1A* promoter methylation was associated with RCC in blood and urine samples (cancer vs nonmalignant controls), which suggested that *RASSF1A* promoter methylation may become a promising noninvasive biomarker for the detection of RCC in the future. According to the results of TSA, additional prospective clinical studies with large sample sizes are required to further investigate whether *RASSF1A* promoter methylation could be used as a biomarker for the diagnosis of RCC based on blood or urine samples.

Finally, we evaluated whether *RASSF1A* promoter methylation was linked to clinicopathologic characteristics and prognosis in patients with RCC. *RASSF1A* promoter methylation did not correlate with age, gender, lymph node status, or distant metastasis. Significant relationships were observed between *RASSF1A* promoter methylation and tumor grade, clinical stage, and T classification, with methylation notably higher in high-grade vs low-grade tumors, advanced vs early-stage patients, and high (pT2--4) vs low (pT1) T classification. These analyses suggest that *RASSF1A* promoter methylation may be closely associated with RCC progression. TSA showed that additional studies are essential to inform the analyses of T classification, but that the analyses of tumor grade, clinical stage, and tumor histology were robust. Additionally, TCGA data showed that *RASSF1A* promoter methylation remained significantly associated with pRCC vs ccRCC (OR=23.19, *P*\<0.001), suggesting that it may play a more important role in the pathogenesis of pRCC. On multivariate analysis, *RASSF1A* promoter methylation was associated with poorer cancer-specific survival among 179 patients with ccRCC patients,[@b31-ott-12-119] but did not correlate with overall survival among 58 patients with ccRCC patients.[@b16-ott-12-119] Further analysis using TCGA data showed that no correlation was found between *RASSF1A* promoter methylation and overall survival on multivariate analysis (HR=0.921, *P*=0.687) in 567 RCCs. More studies using multivariate analysis will be crucial to confirm the prognostic impact of *RASSF1A* promoter methylation on cancer-specific survival.

The current results compare favorably with the previous meta-analyses by Yu et al[@b48-ott-12-119] and Huang et al.[@b49-ott-12-119] Yu et al only analyzed whether *RASSF1A* promoter methylation was correlated with RCC in cancer vs nontumor controls,[@b48-ott-12-119] and *RASSF1A* promoter methylation did not correlate with RCC in tissue samples.[@b48-ott-12-119] Our result involving a greater number of eligible studies with a larger population (15 studies with 1,296 tissue samples) showed that *RASSF1A* promoter methylation was significantly associated with RCC in tissue samples. In addition, Yu et al[@b48-ott-12-119] did not report whether *RASSF1A* promoter methylation was linked to clinical features (eg, gender, tumor grade, clinical stage, T classification, histologic subtypes, lymph node metastasis, and distant metastasis) and did not include an analysis of overall survival. Huang et al only analyzed whethe *RASSF1A* promoter methylation was linked to tumor stage (five studies with 252 cases) and grade (four studies with 190 cases), showing that *RASSF1A* promoter methylation had a borderline significant correlation with tumor stage (*P*=0.051) and a significant association with tumor grade (*P*=0.001).[@b49-ott-12-119] Our meta-analysis involving more patients suggested that *RASSF1A* promoter methylation was significantly linked to tumor grade (13 studies with 686 patients with RCC, *P*\<0.001) and clinical stage (8 studies with 463 patients with RCC, *P*=0.001). Additionally, Huang et al[@b49-ott-12-119] did not analyze whether *RASSF1A* promoter methylation was associated with prognosis (cancer-specific survival or overall survival) or other clinical features such as gender, T stage, and lymph node status.

The current meta-analysis had several limitations. First, the size of the population with blood or urine samples was small. Second, the populations of the included studies mainly consisted of Asians and Caucasians, with limited numbers of other ethnic subgroups, such as Africans. Third, only two studies reported the prognostic role of *RASSF1A* promoter methylation using multivariate analysis in RCC.

Conclusion
==========

The present findings show that *RASSF1A* promoter methylation correlates with RCC in tissue, blood, and urine samples. *RASSF1A* promoter methylation is not linked to age, gender, lymph node status, distant metastasis, or overall survival, but it is associated with tumor grade, clinical stage, T classification, histologic subtypes, and cancer-specific survival on multivariate analysis. Based on TSA, additional studies with large sample sizes are needed to validate these results in cancer vs control blood and urine samples and to confirm the findings regarding T classification and prognosis.
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###### 

Baseline characteristics of the included publications with clinicopathologic features

  Author, year                             Country       Ethnicity       Method       Histology       Sample       Case       ≥50 years                 \<50 years                           
  ---------------------------------------- ------------- --------------- ------------ --------------- ------------ ---------- ------------------------- ------------------------- ----- ---- -----
                                                                                                                                                                                             
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        22                        42    4    8
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        21                        42    4    8
  Dulaimi et al, 2004[@b61-ott-12-119]     USA           Caucasians      MSP          RCC             Tissue       45         99                        40                        86    5    13
  Hori et al, 2007[@b57-ott-12-119]        Japan         Asians          MSP          RCC             Tissue       41         42                        33                        34    8    8
  Onay et al, 2009[@b55-ott-12-119]        Turkey        Caucasians      MSP          RCC             Tissue       11         21                        9                         18    2    3
  Ellinger et al, 2011[@b52-ott-12-119]    Germany       Caucasians      QMSP         pRCC            Tissue       32         32                        26                        26    6    6
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        13                        22    4    5
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **Male**                  **Female**                           
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        16                        34    10   16
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        15                        34    10   16
  Dulaimi et al, 2004[@b61-ott-12-119]     USA           Caucasians      MSP          RCC             Tissue       45         99                        29                        65    16   34
  Hori et al, 2007[@b57-ott-12-119]        Japan         Asians          MSP          RCC             Tissue       41         42                        32                        33    9    9
  Kawai et al, 2010[@b54-ott-12-119]       Japan         Asians          COBRA        ccRCC           Tissue       89         179                       69                        129   20   50
  Ellinger et al, 2011[@b52-ott-12-119]    Germany       Caucasians      QMSP         pRCC            Tissue       32         32                        26                        26    6    6
  Klacz et al, 2016[@b51-ott-12-119]       Poland        Caucasians      MSHRM        ccRCC           Tissue       23         58                        9                         30    14   28
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        11                        13    6    14
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **Grade 3--4**            **Grade 1--2**                       
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Yoon et al, 2001[@b63-ott-12-119]        USA           Caucasians      BSQ          RCC             Tissue       18         32                        6                         8     0    6
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        18                        19    8    26
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        17                        19    8    26
  Dulaimi et al, 2004[@b61-ott-12-119]     USA           Caucasians      MSP          RCC             Tissue       45         99                        24                        36    17   51
  Tokinaga et al, 2004[@b60-ott-12-119]    Japan         Asians          COBRA        ccRCC           Tissue       39         50                        0                         0     20   50
  Loginov et al, 2004[@b59-ott-12-119]     Russia        Caucasians      MSRA         ccRCC           Tissue       50         53                        12                        13    36   38
  Hori et al, 2007[@b57-ott-12-119]        Japan         Asians          MSP          RCC             Tissue       41         42                        13                        13    28   29
  Loginov et al, 2009[@b53-ott-12-119]     Russia        Caucasians      MSP          RCC             Tissue       29         39                        10                        12    19   27
  Onay et al, 2009[@b55-ott-12-119]        Turkey        Caucasians      MSP          RCC             Tissue       11         21                        2                         2     9    19
  Kawai et al, 2010[@b54-ott-12-119]       Japan         Asians          COBRA        ccRCC           Tissue       89         179                       17                        24    69   151
  Ellinger et al, 2011[@b52-ott-12-119]    Germany       Caucasians      QMSP         pRCC            Tissue       32         32                        5                         5     27   27
  Klacz et al, 2016[@b51-ott-12-119]       Poland        Caucasians      MSHRM        ccRCC           Tissue       23         58                        15                        33    8    25
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        5                         8     12   19
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **Stage 3--4**            **Stage 1--2**                       
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        10                        12    16   35
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        9                         12    16   35
  Tokinaga et al, 2004[@b60-ott-12-119]    Japan         Asians          COBRA        ccRCC           Tissue       39         50                        5                         8     15   42
  Loginov et al, 2004[@b59-ott-12-119]     Russia        Caucasians      MSRA         ccRCC           Tissue       50         53                        23                        25    27   28
  Loginov et al, 2009[@b53-ott-12-119]     Russia        Caucasians      MSP          RCC             Tissue       29         39                        17                        21    12   18
  Onay et al, 2009[@b55-ott-12-119]        Turkey        Caucasians      MSP          RCC             Tissue       11         21                        2                         3     9    18
  Kawai et al, 2010[@b54-ott-12-119]       Japan         Asians          COBRA        ccRCC           Tissue       89         179                       32                        52    57   127
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        14                        23    3    4
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **pT2--4**                **pT1**                              
  **M**+                                   **Total**                     **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        14                        17    12   30
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        13                        17    12   30
  Dulaimi et al, 2004[@b61-ott-12-119]     USA           Caucasians      MSP          RCC             Tissue       45         99                        24                        40    20   52
  Hori et al, 2007[@b57-ott-12-119]        Japan         Asians          MSP          RCC             Tissue       41         42                        8                         9     33   33
  Onay et al, 2009[@b55-ott-12-119]        Turkey        Caucasians      MSP          RCC             Tissue       11         21                        11                        21    0    0
  Ellinger et al, 2011[@b52-ott-12-119]    Germany       Caucasians      QMSP         pRCC            Tissue       32         32                        13                        13    19   19
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **pT2--4**                **pT1**                              
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        7                         10    9    15
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **Node**+                 **Node**−                            
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        2                         3     24   44
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        2                         3     23   44
  Dulaimi et al, 2004[@b61-ott-12-119]     USA           Caucasians      MSP          RCC             Tissue       45         99                        5                         8     36   79
  Onay et al, 2009[@b55-ott-12-119]        Turkey        Caucasians      MSP          RCC             Tissue       11         21                        0                         0     11   21
  Kawai et al, 2010[@b54-ott-12-119]       Japan         Asians          COBRA        ccRCC           Tissue       89         179                       8                         12    81   167
  Ellinger et al, 2011[@b52-ott-12-119]    Germany       Caucasians      QMSP         pRCC            Tissue       32         32                        3                         3     29   29
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        0                         1     16   24
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **Distant metastasis**+   **Distant metastasis**−              
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Onay et al, 2009[@b55-ott-12-119]        Turkey        Caucasians      MSP          RCC             Tissue       11         21                        2                         3     9    18
  Kawai et al, 2010[@b54-ott-12-119]       Japan         Asians          COBRA        ccRCC           Tissue       89         179                       14                        24    75   155
  Ellinger et al, 2011[@b52-ott-12-119]    Germany       Caucasians      QMSP         pRCC            Tissue       32         32                        1                         1     31   31
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        3                         3     13   22
                                                                                                                                                                                             
  **Author, year**                         **Country**   **Ethnicity**   **Method**   **Histology**   **Sample**   **Case**   **ccRCC**                 **pRCC**                             
  **M**+                                   **Total**     **M**+          **Total**    **M**+          **Total**                                                                              
                                                                                                                                                                                             
  Morrissey et al, 2001[@b64-ott-12-119]   UK            Caucasians      \#           RCC             Tissue       59         211                       32                        138   12   27
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Tissue       26         50                        17                        35    6    6
  Battagli et al, 2003[@b62-ott-12-119]    USA           Caucasians      MSP          RCC             Urine        25         50                        17                        35    5    6
  Dulaimi et al, 2004[@b61-ott-12-119]     USA           Caucasians      MSP          RCC             Tissue       45         99                        23                        50    14   20
  Gonzalgo et al, 2004[@b58-ott-12-119]    USA           Caucasians      QMSP         RCC             Tissue       30         38                        19                        21    9    9
  Costa et al, 2007[@b56-ott-12-119]       Portugal      Caucasians      QMSP         RCC             Tissue       68         85                        42                        52    13   13
  Hori et al, 2007[@b57-ott-12-119]        Japan         Asians          MSP          RCC             Tissue       41         42                        30                        31    5    5
  Skrypkina et al, 2016[@b50-ott-12-119]   Ukraine       Caucasians      QMSP         RCC             Blood        17         27                        15                        23    1    1

**Notes:** "\#"stands for bisulfite modification, direct sequencing, and restriction enzyme digestion. T classification, pT; node, lymph node status.

**Abbreviations:** BSQ, bisulfite sequencing; ccRCC, clear cell RCC; COBRA, combined bisulfite restriction analysis; M, methylation-positive status; MSHRM, methylation-sensitive high-resolution melting analysis; MSP, methylation-specific polymerase chain reaction; MSRA, methylation-sensitive restriction enzyme analysis; pRCC, papillary RCC; QMSP, quantitative methylation-specific polymerase chain reaction; RCC, renal cell carcinoma.
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![Flow diagram of the study selection procedure.](ott-12-119Fig1){#f1-ott-12-119}

![Forest plot of the association of *RASSF1A* promoter methylation in the RCC vs control group using tissue: OR=5.64, 95% CI=1.82--17.51, *P*=0.003; blood: OR=11.70, 95% CI=4.82--28.39, *P*\<0.001; and urine: OR=17.54, 95% CI=6.60--46.66, *P*\<0.001.\
**Note:** Weights are from random-effects analysis.\
**Abbreviation:** RCC, renal cell carcinoma.](ott-12-119Fig2){#f2-ott-12-119}

![Forest plot of the association of *RASSF1A* promoter methylation with age (OR=1.00, 95% CI=0.50--2.04, *P*=0.99) and gender (OR=0.95, 95% CI=0.51--1.76, *P*=0.86) in RCC.\
**Note:** Weights are from random-effects analysis.\
**Abbreviation:** RCC, renal cell carcinoma.](ott-12-119Fig3){#f3-ott-12-119}

![Forest plot of the association of *RASSF1A* promoter methylation with lymph node metastasis (OR=1.72, 95% CI=0.76--3.87, *P*=0.192) and distant metastasis (OR=1.66, 95% CI=0.75--3.69, *P*=0.21) in RCC.\
**Note:** Weights are from random-effects analysis.\
**Abbreviation:** RCC, renal cell carcinoma.](ott-12-119Fig4){#f4-ott-12-119}

![Forest plot of the correlation of *RASSF1A* promoter methylation with tumor grade (OR=3.59, 95% CI=1.85--6.95, *P*\<0.001) and clinical stage (OR=2.15, 95% CI=1.34--3.45, *P*=0.001) in RCC.\
**Note:** Weights are from random-effects analysis.\
**Abbreviation:** RCC, renal cell carcinoma.](ott-12-119Fig5){#f5-ott-12-119}

![Forest plot of the correlation of *RASSF1A* promoter methylation with T classification (OR=2.66, 95% CI=1.11--6.39, *P*=0.029) and histologic subtypes (OR=2.91, 95% CI=1.61--5.23, *P*\<0.001) in RCC.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** ccRCC, clear cell RCC; pRCC, papillary RCC; RCC, renal cell carcinoma.](ott-12-119Fig6){#f6-ott-12-119}

![Forest plot of potential publication bias using Egger's test in RCC vs control tissue samples (*P*=0.782) and in relation to tumor grade (*P*=0.547).\
**Abbreviation:** RCC, renal cell carcinoma.](ott-12-119Fig7){#f7-ott-12-119}

![Trial sequential analysis assessing the required sample information in relation to cancer vs control tissue, blood, and urine samples, T classification, tumor grade, and clinical stage.\
**Abbreviations:** APIS, a priori anticipated information size; RRR, relative risk reduction.](ott-12-119Fig8){#f8-ott-12-119}

![Trial sequential analysis assessing the required sample information in relation to tumor histology.\
**Abbreviations:** APIS, a priori anticipated information size; RRR, relative risk reduction.](ott-12-119Fig9){#f9-ott-12-119}

###### 

Baseline characteristics of the included publications

  First author                              Country    Ethnicity    Age     Stage   Method   Histology   Sample   Control type      Cancer       Control     Clinical features   MA (survival)
  ----------------------------------------- ---------- ------------ ------- ------- -------- ----------- -------- ----------------- ------------ ----------- ------------------- ---------------
                                                                                                                                                                                 
  Morrissey et al, 2001[@b43-ott-12-119]    UK         Caucasians   NA      NA      \#       RCC         Tissue   Adjacent normal   211 (28)     80 (2.5)    Yes                 NA
  Yoon et al, 2001[@b42-ott-12-119]         USA        Caucasians   NA      NA      BSQ      RCC         Tissue   Normal            32 (56.3)    10 (0)      Yes                 NA
  Battagli et al, 2003[@b41-ott-12-119]     USA        Caucasians   NA      1--4    MSP      RCC         Tissue   Normal            50 (52)      15 (0)      Yes                 NA
  Battagli et al, 2003[@b41-ott-12-119]     USA        Caucasians   NA      1--4    MSP      RCC         Urine    Nonmalignant      50 (50)      24 (0)      Yes                 NA
  Yano et al, 2004[@b40-ott-12-119]         Japan      Asians       NA      NA      MSP      RCC         Tissue   Adjacent normal   29 (65.5)    29 (6.9)    NA                  NA
  Dulaimi et al, 2004[@b39-ott-12-119]      USA        Caucasians   NA      NA      MSP      RCC         Tissue   Normal            99 (45.5)    15 (0)      Yes                 NA
  Hoque et al, 2004[@b17-ott-12-119]        USA        Caucasians   NA      NA      QMSP     RCC         Urine    Nonmalignant      26 (65.4)    91 (11)     NA                  NA
  Hoque et al, 2004[@b17-ott-12-119]        USA        Caucasians   NA      NA      QMSP     RCC         Blood    Nonmalignant      18 (11.1)    30 (3.3)    NA                  NA
  Tokinaga et al, 2004[@b38-ott-12-119]     Japan      Asians       NA      1--4    COBRA    ccRCC       Tissue   Adjacent normal   50 (78)      39 (97.4)   Yes                 NA
  Loginov et al, 2004[@b37-ott-12-119]      Russia     Caucasians   NA      1--4    MSRA     ccRCC       Tissue   Adjacent normal   53 (94.3)    30 (33.3)   Yes                 NA
  Gonzalgo et al, 2004[@b36-ott-12-119]     USA        Caucasians   61.1    \>1     QMSP     RCC         Tissue   Adjacent normal   38 (78.9)    22 (90.9)   Yes                 NA
  Peters et al, 2007[@b34-ott-12-119]       Germany    Caucasians   NA      NA      COBRA    RCC         Tissue   Adjacent normal   45 (97.8)    45 (97.8)   NA                  NA
  Costa et al, 2007[@b33-ott-12-119]        Portugal   Caucasians   61      1--4    QMSP     RCC         Tissue   Adjacent normal   85 (80)      62 (100)    Yes                 NA
  Hori et al, 2007[@b35-ott-12-119]         Japan      Asians       NA      NA      MSP      RCC         Tissue   NA                42 (97.6)    NA          Yes                 NA
  Duan et al, 2007[@b44-ott-12-119]         China      Asians       55      1--4    MSP      RCC         Tissue   Adjacent normal   26 (65.4)    26 (0)      NA                  NA
  Yuan et al, 2008[@b45-ott-12-119]         China      Asians       NA      NA      MSP      RCC         Tissue   Adjacent normal   19 (52.6)    19 (0)      NA                  NA
  Loginov et al, 2009[@b19-ott-12-119]      Russia     Caucasians   NA      1--4    MSP      RCC         Tissue   Adjacent normal   39 (74.4)    39 (15.4)   Yes                 NA
  Onay et al, 2009[@b32-ott-12-119]         Turkey     Caucasians   59.2    1--3    MSP      RCC         Tissue   Adjacent normal   21 (52.4)    21 (38.1)   Yes                 NA
  Kawai et al, 2010[@b31-ott-12-119]        Japan      Asians       65      1--4    COBRA    ccRCC       Tissue   NA                179 (49.7)   NA          Yes                 Yes
  Ellinger et al, 2011[@b18-ott-12-119]     Germany    Caucasians   60.5    1--3    QMSP     pRCC        Tissue   Adjacent normal   32 (100)     15 (93.3)   Yes                 NA
  de Martino et al, 2012[@b30-ott-12-119]   Austria    Caucasians   64.7    1--3    QMSP     RCC         Blood    Nonmalignant      157 (45.9)   43 (7)      NA                  NA
  Hauser et al, 2013[@b29-ott-12-119]       Germany    Caucasians   66      NA      MSRA     RCC         Blood    Healthy           35 (22.9)    54 (1.9)    NA                  NA
  Klacz et al, 2016[@b16-ott-12-119]        Poland     Caucasians   62.16   NA      MSHRM    ccRCC       Tissue   NA                58 (39.7)    NA          Yes                 Yes
  Skrypkina et al, 2016[@b15-ott-12-119]    Ukraine    Caucasians   NA      2--3    QMSP     RCC         Blood    Healthy           27 (63)      15 (6.7)    Yes                 NA

**Note:** "\#" stands for bisulfite modification, direct sequencing, and restriction enzyme digestion.

**Abbreviations:** BSQ, bisulfite sequencing; ccRCC, clear cell RCC; COBRA, combined bisulfite restriction analysis; M, methylation-positive status; MA, multivariate analysis; MSHRM, methylation-sensitive high-resolution melting analysis; MSP, methylation-specific polymerase chain reaction; MSRA, methylation-sensitive restriction enzyme analysis; NA, not applicable; pRCC, papillary RCC; QMSP, quantitative methylation-specific polymerase chain reaction; RCC, renal cell carcinoma.

###### 

Subgroup analyses of *RASSF1A* promoter methylation in cancer vs control tissue samples

  Subgroup analyses   Pooled OR (95% CI)    Heterogeneity (*P*)   *P*-value   Cases   Controls
  ------------------- --------------------- --------------------- ----------- ------- ----------
                                                                                      
  Ethnicity                                                                           
   Caucasians         4.90 (1.45--16.64)    \<0.001               0.011       705     354
   Asians             9.27 (0.35--243.63)   \<0.001               0.182       124     113
  Testing method                                                                      
   Non-MSP            1.85 (0.27--12.48)    \<0.001               0.527       546     303
   MSP                16.32 (5.25--50.69)   0.028                 \<0.001     283     164

**Abbreviation:** MSP, methylation-specific polymerase chain reaction.

###### 

Association between *RASSF1A* methylation and clinical pathological characteristics from TCGA dataset

  Clinical characteristics                            Total (n)   OR with 95% CI        *P*-value
  --------------------------------------------------- ----------- --------------------- -----------
                                                                                        
  Gender (male vs female)                             594         1.35 (0.95--1.91)     0.094
  Tumor stage (stage 3--4 vs stage 1--2)              594         0.67 (0.47--0.94)     0.023
  Tumor histology (papillary RCC vs clear cell RCC)   568         23.19 (15.07--35.7)   \<0.001

**Note:** n, the number of the study population.

**Abbreviations:** RCC, renal cell cancer; TCGA, The Cancer Genome Atlas.

[^1]: These authors contributed equally to this work
